钆塞酸增强磁共振成像定量测量慢性乙型肝炎患者肝纤维化:天冬氨酸氨基转移酶与血小板比值指数及纤维化-4指数的对比研究
该研究纳入81例慢性乙型肝炎患者,在3T钆塞酸增强磁共振成像上通过变异系数图定量测量肝实质信号不均匀性,并与天冬氨酸氨基转移酶与血小板比值指数(APRI)和纤维化-4指数(FIB-4)进行对比。变异系数均值与APRI(r=0.392,p<0.001)和FIB-4(r=0.294,p<0.001)相关,在显著纤维化组中基于APRI和FIB-4的受试者工作特征曲线下面积分别为0.875和0.831。作者认为变异系数图与APRI和FIB-4呈中度相关,可用于定量测量慢性乙型肝炎患者的肝纤维化。
要点
- 钆塞酸增强磁共振变异系数图可定量反映肝实质信号不均匀性,与APRI和FIB-4呈中度相关。
- 按APRI分组,对照组及I、II、III组变异系数均值分别为4.08±0.92、4.24±0.80、5.64±1.11、5.73±1.28(p<0.001)。
- 显著纤维化组中,变异系数图基于APRI的曲线下面积为0.875,基于FIB-4的曲线下面积为0.831。
核心结论
- 钆塞酸增强磁共振变异系数图与APRI和FIB-4值呈中度相关,可用于定量测量慢性乙型肝炎患者的肝纤维化。
研究设计与样本
- 本研究为在3T钆塞酸增强磁共振成像上开展的研究,纳入81例慢性乙型肝炎感染患者,以APRI和FIB-4为参照进行分组比较,并基于荟萃回归结果对APRI与FIB-4进行比较分析。
关键影像表现/征象
- 在磁共振图像上,通过肝脏实质变异系数图计算信号不均匀性以定量测量肝纤维化。
- 按APRI分组,对照组及I、II、III组的变异系数均值分别为4.08±0.92、4.24±0.80、5.64±1.11、5.73±1.28(p<0.001)。
- 按FIB-4分组,A、B、C组的变异系数均值分别为4.22±0.95、5.40±1.19、5.71±1.17(p<0.001)。
诊断标准与关键数值
- 变异系数均值与APRI相关(r=0.392,p<0.001),与FIB-4相关(r=0.294,p<0.001)。
- 显著纤维化组中,受试者工作特征曲线分析显示基于APRI的曲线下面积为0.875,基于FIB-4的曲线下面积为0.831。
临床应用与阅片要点
- 作者认为钆塞酸增强磁共振变异系数图可用于定量测量慢性乙型肝炎患者的肝纤维化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To quantitatively measure hepatic fibrosis on gadoxetic acid-enhanced magnetic resonance (MR) in chronic hepatitis B (CHB) patients and identify the correlations with aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4) values.
MATERIALS AND METHODS: This study on gadoxetic acid-enhanced 3T MR imaging included 81 patients with CHB infection. To quantitatively measure hepatic fibrosis, MR images were analyzed with an aim to identify inhomogeneous signal intensities calculated from a coefficient of variation (CV) map in the liver parenchyma. We also carried out a comparative analysis between APRI and FIB-4 based on metaregression results. The diagnostic performance of the CV map was evaluated using a receiver-operating characteristic (ROC) curve.
RESULTS: In the MR images, the mean CV values in control, groups I, II, and III based on APRI were 4.08 ± 0.92, 4.24 ± 0.80, 5.64 ± 1.11, and 5.73 ± 1.28, respectively (p < 0.001). In CHB patients grouped by FIB-4, the mean CV values of groups A, B, and C were 4.22 ± 0.95, 5.40 ± 1.19, and 5.71 ± 1.17, respectively (p < 0.001). The mean CV values correlated well with APRI (r = 0.392, p < 0.001) and FIB-4 (r = 0.294, p < 0.001). In significant fibrosis group, ROC curve analysis yielded an area under the curve of 0.875 using APRI and 0.831 using FIB-4 in HB, respectively.
CONCLUSION: Gadoxetic acid-enhanced MR imaging for calculating a CV map showed moderate correlation with APRI and FIB-4 values and could be employed to quantitatively measure hepatic fibrosis in patients with CHB.
引用
- Lee GM, Kim YR, Ryu JH, et al. Quantitative Measurement of Hepatic Fibrosis with Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Patients with Chronic Hepatitis B Infection: A Comparative Study on Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index. Korean J Radiol. 2017. PMID: 28458596. doi:10.3348/kjr.2017.18.3.444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。